Morningstar

CureVac NV Ordinary Shares CVAC

Morningstar Rating
Unlock
Stock XNAS Rating as of
$3.02 +0.06 (2.03%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

CureVac Continues to Burn Cash; Provides Very Risk-Tolerant Investors With Exposure to mRNA Pipeline

Rachel Elfman

CureVac was founded in 2000, and its focus is on developing vaccines and therapies using messenger ribonucleic acid, or mRNA. mRNA offers several advantages, including cell-free, rapid, large-scale manufacturing and the ability to substitute new genetic sequences to create novel vaccines. Vaccines are typically composed of weakened viruses or proteins (antigens) that they express. In mRNA vaccines, the genetic code for an antigen is administered to patients who then manufacture the antigen themselves, which triggers an immune response.

Read Full Report

Price vs Fair Value

View History
CVAC is trading at a 547% premium.
Price
$3.02
Fair Value
$3.59
Uncertainty
Extreme
1-Star Price
$58.82
5-Star Price
$9.74
Economic Moat
Lmmx
Capital Allocation
Jpqhngly

Bulls Say, Bears Say

Bulls

Partnerships allow CureVac to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

CureVac's mRNA oncology vaccine candidates could face competition from BioNTech and Moderna.

Show More

News

View All

Trading Information

Previous Close Price
$2.96
Day Range
$2.96–3.07
52-Week Range
$2.22–6.44
Bid/Ask
$2.96 / $3.04
Market Cap
$677.43 Mil
Volume/Avg
345,524 / 632,707

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
9.50
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
1,100
Website
https://www.curevac.com

Competitors

Valuation

View More
Metric
CVAC
MRNA
BNTX
Price/Earnings (Normalized)
 ——38.69
Price/Book Value
 1.681.971.43
Price/Sales
 9.504.6110.20
Price/Cash Flow
 ——50.07
Price/Earnings
CVAC
MRNA
BNTX

Financial Strength

Metric
CVAC
MRNA
BNTX
Quick Ratio
 2.233.777.25
Current Ratio
 2.294.097.54
Interest Coverage
 −1,137.74−169.39—
Quick Ratio
CVAC
MRNA
BNTX

Profitability

Metric
CVAC
MRNA
BNTX
Return on Assets (Normalized)
 −29.99%−29.83%−1.51%
Return on Equity (Normalized)
 −43.71%−39.97%−1.70%
Return on Invested Capital (Normalized)
 −42.20%−38.74%−4.02%
Return on Assets
CVAC
MRNA
BNTX

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
ChwqpyqlsRsvy$512.4 Bil
 Vertex Pharmaceuticals Inc
VRTX
RxhxtzmxvCvsjkrd$117.5 Bil
 Regeneron Pharmaceuticals Inc
REGN
YrhlywwkBgszdxy$111.6 Bil
 Alnylam Pharmaceuticals Inc
ALNY
YdsdrptwvRdchxfg$34.4 Bil
 argenx SE ADR
ARGX
QlzddlsRwdb$31.7 Bil
 BioNTech SE ADR
BNTX
GqvtfpmNck$29.2 Bil
 Moderna Inc
MRNA
PnpnsszbjRhfcb$23.1 Bil
 United Therapeutics Corp
UTHR
RfljfhzmJgkh$15.8 Bil
 Biomarin Pharmaceutical Inc
BMRN
BlcjbxrjwWgvrh$13.2 Bil
 Incyte Corp
INCY
ZnfgqqjClmzcq$13.0 Bil

Sponsor Center